+44-330-822-4832
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi Research Article
New Aspects of Therapy of Hepatocellular Carcinoma Egyptian Patients
| Ragaa Hosny Mohamad1*, Mohamad Gamil Abdelmoneim El-Said2, Zekry Khalid Zekry3, Amal Mohamad Al-Bastawesy4, Rashwan Mohamad Farag5, Hussien Abdel-RahmanAl-Mehdar6, Abdulbaset Abdelsalam Elfighia7, Yahia Mahmoud Ismail8, Elsayed Ibrahim Elshayeb 9, Abdel Fatah Mohsen Badawy10, Sabry Mohamad Sharawy1 and Mahmoud Mohamad Elmarzabani11 | |
| 1Clinical Biochemistry, Cancer Biology, National Cancer Institute, Cairo University, Egypt | |
| 2Surgical Oncology National Cancer Institute, Cairo University, Egypt | |
| 3Medical Oncology, National Cancer Institute, Cairo University, Egypt | |
| 4Food Technology Research Centre, Cairo University, Egypt | |
| 5Medical Biochemistry, Ain Shams University, Egypt | |
| 6Faculty of science, Biology Department, Immunology Unit, King Abdulaziz University, Jeddah, Saudi Arabia | |
| 7Medical Biochemistry, Tripoli University, Libya | |
| 8Medical Oncology, National Cancer Institute, Cairo University, Egypt | |
| 9Internal Medicine, Faculty of Medicine, Menofyia University, Egypt | |
| 10Organic Chemistry, Petroleum Research Centre, Egypt | |
| 11Drug Research and Experimental Pharmacology, National Cancer Institute, Cairo University, Egypt | |
| *Corresponding Author : | Ragaa Hosny Mohamad Mohamadeen Al-Tahtawy Cancer Biology Department National Cancer Institute Cairo University, Fom Al-Khalig Street Post No:11234, Cairo, Egypt Tel: 0020100185686 Fax: +0223644720 E-mail: ragaatahtawy@gmail.com/td> |
| Received May 14, 2014; Accepted December 30, 2014; Published January 06, 2015 | |
| Citation: Mohamad RH, El-Said MGA, Zekry ZK, Al-Bastawesy AM, Farag RM, et al. (2015) New Aspects of Therapy of Hepatocellular Carcinoma Egyptian Patients. Biochem Physiol 4:150. doi:10.4172/2168-9652.1000150 | |
| Copyright: © 2015 Mohamad RH, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. | |
Abstract
Background: The purpose of this study was design to investigate the potential impact of chemo and hormonal therapy drugs either with natural oils or other with vitamin E on HCC Egyptian patients.
Methods: A retrospective analysis of medical records was performed on 100 unresectable HCC Egyptian patients in stage A or B who were identified through the National Cancer Institute Cairo University and Menoufia University, from 2010 to 2013. All of patients had been received systemic chemo and hormonal and therapy (5-fluorouracil, Oxaloplatin and tamoxifen) either with five type of natural oils or other with vitamin E. Clinical picture , hematological test, metabolic parameters, telomerase activity, VEGF, MAD, GSH, zinc, ER ,PR, KRAS, BRAF and NRAS has been assessed. Survival curves were also analyzed at pre-and post-treatment. All patients were applied to do regular exercise, control their diet before receiving treatment. The survival rate was determined.
Results: the present data indicate that oral NS.O and CUR.O showed greatly kept hematological finding, serum levels of telomerase activity, VEGF, GSH, MAD ALT, AST, GGT, bilirubin, albumin and zinc to the normal levels (p < 0.001), the toxicity has been reduced without affecting response to chemo and hormonal therapy and survival , the quality of life, clinical picture and survival seemed to be better.Fortunately the depletion in the serum levels of the VEGF and the telomerase activity correlates with good of clinical picture compared with other groups under investigation.
Conclusion: Using Chemo and hormonal therapy, in combination with oral NS.O and CUR.O was identified as the most suitable treatment for HCC patients resulted in improving survival, maximizing clinical benefit, and minimizing risk of chemo and hormonal therapy toxicity. The telomerase activity and VEGF levels can be used as markers to predict survival and response to treatment in HCC patients in the future.
